Gilead Sciences just paid $11.9 billion to acquire Kite Pharma. At $180 a share, that price represents a 29.4 percent premium over Kite's closing share price on Friday, according to Reuters.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.
Vox reports on inequities in genetic research and efforts to address them.
The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.
In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.